AzurRx BioPharma Inc (NASDAQ:AZRX) has received a consensus broker rating score of 1.00 (Strong Buy) from the one brokers that cover the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong buy recommendation.

Analysts have set a 12 month consensus target price of $8.25 for the company and are forecasting that the company will post ($0.23) EPS for the current quarter, according to Zacks. Zacks has also given AzurRx BioPharma an industry rank of 158 out of 265 based on the ratings given to its competitors.

Separately, HC Wainwright set a $8.00 price objective on AzurRx BioPharma and gave the stock a “buy” rating in a research note on Friday, November 17th.

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. IHT Wealth Management LLC boosted its position in AzurRx BioPharma by 15.3% during the 2nd quarter. IHT Wealth Management LLC now owns 3,498 shares of the company’s stock valued at $486,000 after acquiring an additional 464 shares in the last quarter. Susquehanna International Group LLP bought a new stake in AzurRx BioPharma during the 3rd quarter valued at $131,000. Ardsley Advisory Partners bought a new stake in AzurRx BioPharma during the 2nd quarter valued at $141,000. Finally, Parsons Capital Management Inc. RI lifted its holdings in shares of AzurRx BioPharma by 37.2% during the 3rd quarter. Parsons Capital Management Inc. RI now owns 254,263 shares of the company’s stock valued at $1,015,000 after purchasing an additional 68,920 shares during the last quarter. 8.18% of the stock is currently owned by institutional investors and hedge funds.

Shares of AzurRx BioPharma (NASDAQ AZRX) traded up $0.02 during trading hours on Friday, reaching $3.71. The company had a trading volume of 36,100 shares, compared to its average volume of 60,367. AzurRx BioPharma has a 52 week low of $2.40 and a 52 week high of $5.25.

TRADEMARK VIOLATION NOTICE: This story was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this story can be accessed at https://www.americanbankingnews.com/2018/01/05/brokerages-set-8-25-target-price-for-azurrx-biopharma-inc-azrx.html.

AzurRx BioPharma Company Profile

AzurRx BioPharma, Inc is a clinical development-stage biopharmaceutical company. The Company is engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal (GI) disorders. The Company’s product pipeline consists of two therapeutic proteins, such as MS1819 and AZX1101.

Get a free copy of the Zacks research report on AzurRx BioPharma (AZRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for AzurRx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AzurRx BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.